When does Japan start covering Elevidys and who qualifies?

Coverage begins on February 20. Eligibility is limited to ambulant children aged 3 to 7 with Duchenne muscular dystrophy, treated at qualified centers. Access requires documented diagnosis, pre-infusion testing, informed consent, and site readiness for monitoring and steroids. Enrollment will concentrate at major hospitals first.

How much does Elevidys cost in Japan and what will families pay?

The list price is ¥304.97 million per patient. Out-of-pocket costs are governed by national high-cost medical expense caps, and many municipalities offer child subsidies that can reduce co-pays. Families should confirm exact obligations with their insurer and local office before scheduling treatment.

What does this mean for NHI budgets and biotech revenues?

Budget impact depends on treated volume. At 30, 50, and 100 patients, gross spend equals about ¥9.15 billion, ¥15.25 billion, and ¥30.50 billion at list. For Sarepta Elevidys, revenue timing will track hospital readiness, referrals, and real-world outcomes that support broader clinical confidence.

What should investors watch after Elevidys Japan insurance cover begins?

Focus on hospital onboarding, monthly infusion starts, and any guidance from health authorities. Monitor safety summaries and functional outcomes in treated children. Also watch policy meetings and price surveys that influence Japan drug pricing. These signals will shape adoption pace and revenue visibility.

Global Market Insights

February 20: Japan Covers Elevidys at ¥304.97M, Gene Therapy Price Record

ByDanny Kontos February 19, 2026February 19, 2026

Elevidys Japan insurance cover begins on February 20, setting a record ¥304.97 million list price for a one-time Duchenne gene therapy. National insurance coverage applies to ambulant children aged 3 to 7, a narrow group that will shape near-term uptake. For investors, this decision signals how Japan drug pricing treats high-cost, single-dose treatments. We see three themes to watch: hospital readiness, payer budget exposure, and revenue timing for Sarepta Elevidys. Clarity on logistics and patient identification will be critical in the next few quarters.